文献速递临床生化临床免疫质量管理与危急值

Simoa与Lumipulse检测血浆及脑脊液神经丝轻链的跨平台比较

Plasma and CSF neurofilament light chain measured by Simoa and Lumipulse: an inter-platform comparison across neurological disorders.
PubMed 文献 · Clin Chem Lab Med · 2026-10-30

该研究纳入383名受试者(含健康对照及神经退行性疾病、多发性硬化、缺血性卒中患者),用Simoa和Lumipulse检测血浆NfL,其中92人有配对脑脊液数据。两平台血浆NfL相关性ρ=0.90,但Lumipulse绝对值系统性偏高,存在恒定与比例偏倚。结论认为两平台信号一致但绝对值不同,临床需按平台和年龄解读。

要点

  • Simoa与Lumipulse血浆NfL相关性ρ=0.90,但Lumipulse绝对值系统性偏高。
  • 两平台血浆与脑脊液NfL均显著相关(Simoa ρ=0.72;Lumipulse ρ=0.77)。
  • 临床解读NfL需考虑检测平台差异并结合年龄。

核心结论

  • Simoa与Lumipulse在多种神经系统疾病中捕获一致的血浆NfL信号,但绝对浓度不同,支持临床按平台特异性和年龄感知进行解读。

研究设计与样本

  • 研究纳入383名个体,包括健康对照及神经退行性疾病、多发性硬化、缺血性卒中患者;所有参与者用Simoa和Lumipulse检测血浆NfL,92人有配对脑脊液检测。
  • 按CLSI EP15评估Lumipulse中间精密度和日间重复性;用Spearman相关、Passing-Bablok回归和Bland-Altman分析评估跨平台一致性。

主要发现

  • 全队列血浆NfL两平台高度一致(ρ=0.90),配对样本脑脊液一致性同样强(ρ=0.90)。
  • 方法学比较显示存在恒定和比例偏倚,Lumipulse测得的血浆NfL绝对值系统性更高。
  • 各平台内血浆与脑脊液NfL显著相关(Simoa ρ=0.72;Lumipulse ρ=0.77)。
  • Lumipulse血液和脑脊液检测显示高精密度。
  • 两平台均显示血浆NfL随年龄增长而升高,且神经系统疾病患者高于健康对照。

关键数值与推荐

  • 血浆NfL两平台Spearman相关系数ρ=0.90;配对脑脊液ρ=0.90。
  • 血浆与脑脊液NfL相关性:Simoa ρ=0.72,Lumipulse ρ=0.77。
  • Lumipulse检测存在恒定与比例偏倚,血浆NfL绝对值系统性高于Simoa。

临床怎么用

  • 临床解读血浆NfL结果时应考虑检测平台差异,不可直接跨平台比较绝对值。
  • 应结合年龄因素解读血浆NfL水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Blood neurofilament light chain (NfL) is an accessible biomarker of neuroaxonal injury, but clinical implementation requires robust analytical comparability across platforms. We evaluated plasma NfL measured by Simoa and Lumipulse across neurological disorders, including paired CSF analyses to anchor plasma findings to the central compartment. METHODS: We included 383 individuals, comprising healthy controls and patients with neurodegenerative diseases, multiple sclerosis, and ischemic stroke. Plasma NfL was measured in all participants using Simoa and Lumipulse; paired CSF measurements were available in 92 individuals. Lumipulse intermediate precision and between-day repeatability were assessed according to CLSI EP15. Cross-platform agreement was evaluated using Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis. Plasma-CSF associations and age-adjusted diagnostic differences were assessed separately for each platform. RESULTS: Plasma NfL measured by Simoa and Lumipulse showed strong concordance in the whole cohort (ρ=0.90), with similarly strong CSF concordance in paired samples (ρ=0.90). Method-comparison analyses demonstrated constant and proportional bias, with systematically higher absolute plasma NfL values measured by Lumipulse. Plasma and CSF NfL were significantly correlated within each platform (ρ=0.72 for Simoa; ρ=0.77 for Lumipulse). Lumipulse blood and CSF assays showed high precision. Across both platforms, plasma NfL increased with age and was higher in neurological disorders than in healthy controls. CONCLUSIONS: Simoa and Lumipulse capture a consistent plasma NfL signal across neurological disorders, but absolute concentrations differ, supporting platform-specific, age-aware interpretation in clinical practice.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Toja A, Quaresima V, Tolassi C, et al. Plasma and CSF neurofilament light chain measured by Simoa and Lumipulse: an inter-platform comparison across neurological disorders. Clin Chem Lab Med. 2026. PMID: 42960454. doi:10.1515/cclm-2026-1045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。